Pathology analysis for mesothelioma study in the United Kingdom: Current practice and historical development

References

• Arif, Q., and A. N. Husain. 2015. Malignant mesothelioma diagnosis. Archives of Pathology & Laboratory Medicine 139:978–80. doi:10.5858/arpa.2013-0381-RA.
   PubMed Web of Science ®Google Scholar
• Burdorf, A., B. Jarvholm, and S. Siesling. 2007. Asbestos exposure and differences in occurrence of peritoneal mesothelioma between men and women across countries. Occupational and Environmental Medicine 64:839–42. doi:10.1136/oem.2006.031724.
   PubMed Web of Science ®Google Scholar
• Chenard-Neu, M. P., A. Kabou, A. Mechine, F. Brolly, B. Orion, and J. P. Bellocq. 1998. Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies. Annales de Pathologie 18:460–65.
   PubMedGoogle Scholar
• Clover, J., J. Oates, and C. Edwards. 1997. Anti-cytokeratin 5/6: A positive marker for epithelioid mesothelioma. Histopathology 31:140–43. doi:10.1046/j.1365-2559.1997.2150833.x.
   PubMed Web of Science ®Google Scholar
• Comin, C. E., L. Novelli, A. Cavazza, M. Rotellini, F. Cianchi, and L. Messerini. 2014. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: An immunohistochemical study in comparison with epithelioid pleural mesothelioma. Tumori 100:559–67.
   PubMed Web of Science ®Google Scholar
• Doglioni, C., A. P. Tos, L. Laurino, P. Iuzzolino, C. Chiarelli, M. R. Celio, and G. Viale. 1996. Calretinin: A novel immunocytochemical marker for mesothelioma. American Journal of Surgical Pathology 20:1037–46. doi:10.1097/00000478-199609000-00001.
   PubMed Web of Science ®Google Scholar
• Dragon, J., J. Thompson, M. MacPherson, and A. Shukla. 2015. Differential susceptibility of human pleural and peritoneal mesothelial cells to asbestos exposure. Journal of Cellular Biochemistry 116:1540–52. doi:10.1002/jcb.v116.8.
   PubMed Web of Science ®Google Scholar
• Gilham, C., C. Rake, G. Burdett, A. G. Nicholson, L. Davison, A. Franchini, J. Carpenter, J. Hodgson, A. Darnton, and J. Peto. 2015. Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden. Occupational and Environmental Medicine. doi:10.1136/oemed-2015-103074.
   PubMed Web of Science ®Google Scholar
• Gotzos, V., P. Vogt, and M. R. Celio. 1996. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathology Research and Practice 192:137–47. doi:10.1016/S0344-0338(96)80208-1.
   PubMed Web of Science ®Google Scholar
• Hasteh, F., G. Y. Lin, N. Weidner, and C. W. Michael. 2010. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathology 118:90–96. doi:10.1002/cncy.20071.
   PubMed Web of Science ®Google Scholar
• Hemminki, K., and X. Li. 2003. Time trends and occupational risk factors for peritoneal mesothelioma in Sweden. Journal of Occupational and Environmental Medicine 45:451–55. doi:10.1097/01.jom.0000052960.59271.d4.
   PubMed Web of Science ®Google Scholar
• Henderson, D. W., G. Reid, S. C. Kao, N. van Zandwijk, and S. Klebe. 2013. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. Journal of Clinical Pathology 66:847–53. doi:10.1136/jclinpath-2012-201303.
   PubMed Web of Science ®Google Scholar
• Hjerpe, A., V. Ascoli, C. W. Bedrossian, M. E. Boon, J. Creaney, B. Davidson, A. Dejmek, K. Dobra, A. Fassina, A. Field, P. Firat, T. Kamei, T. Kobayashi, C. W. Michael, S. Onder, A. Segal, P. Vielh, International Mesothelioma Interest Group, International Academy of Cytology, and Papanicolaou Society of Cytopathology. 2015. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. Acta Cytologica 59:2–16.
   PubMedGoogle Scholar
• Husain, A. N., T. Colby, N. Ordonez, T. Krausz, R. Attanoos, M. B. Beasley, A. C. Borczuk, K. Butnor, P. T. Cagle, L. R. Chirieac, A. Churg, S. Dacic, A. Fraire, F. Galateau-Salle, A. Gibbs, A. Gown, S. Hammar, L. Litzky, A. M. Marchevsky, A. G. Nicholson, V. Roggli, W. D. Travis, M. Wick, and International Mesothelioma Interest Group. 2013. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 Update of the consensus statement from the International Mesothelioma Interest Group. Archives of Pathology & Laboratory Medicine 137:647–67. doi:10.5858/arpa.2012-0214-OA.
   PubMed Web of Science ®Google Scholar
• Ihemelandu, C., L. Bijelic, and P. H. Sugarbaker. 2015. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: Clinicopathologic characteristics and survival outcome. Annals of Surgical Oncology 22:1680–85. doi:10.1245/s10434-014-3977-y.
   PubMed Web of Science ®Google Scholar
• Klebe, S., A. Swalling, L. Jonavicius, and D. W. Henderson. 2016. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma. Journal of Clinical Pathology 69:136–41.
   PubMed Web of Science ®Google Scholar
• Labrèche, F., B. W. Case, G. Ostiguy, J. Chalaoui, M. Camus, and J. Siemiatycki. 2012. Pleural mesothelioma surveillance: Validity of cases from a tumour registry. Canadian Respiratory Journal 19:103–07. doi:10.1155/2012/650935.
   PubMed Web of Science ®Google Scholar
• Linton, A., S. Kao, J. Vardy, S. Clarke, N. van Zandwijk, and S. Klebe. 2013. Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review. Asia-Pacific Journal of Clinical Oncology 9:273–79. doi:10.1111/ajco.2013.9.issue-3.
   PubMed Web of Science ®Google Scholar
• McCaughey, W. T. 1958. Primary tumours of the pleura. Journal of Pathology and Bacteriology 76:517–29. doi:10.1002/(ISSN)1555-2039.
   PubMedGoogle Scholar
• Miettinen, M., and M. Sarlomo-Rikala. 2003. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: An immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. American Journal of Surgical Pathology 27:150–58. doi:10.1097/00000478-200302000-00002.
   PubMed Web of Science ®Google Scholar
• Moll, R., D. Dhouailly, and T.-T. Sun. 1989. Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas. An immunohistochemical study using monoclonal antibody AE14. Virchows Archiv B Cell Pathology Including Molecular Pathology 58:129–45. doi:10.1007/BF02890064.
   PubMedGoogle Scholar
• Moolgavkar, S. H., R. Meza, and J. Turim. 2009. Pleural and peritoneal mesotheliomas in SEER: Age effects and temporal trends, 1973-2005. Cancer Causes Control 20:935–44. doi:10.1007/s10552-009-9328-9.
   PubMed Web of Science ®Google Scholar
• Oczypok, E. A., and T. D. Oury. 2015. Electron microscopy remains the gold standard for the diagnosis of epithelial malignant mesothelioma: A case study. Ultrastructural Pathology 39:153–58. doi:10.3109/01913123.2014.960542.
   PubMed Web of Science ®Google Scholar
• Ordóñez, N. G. 1999. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma: review and update. American Journal of Clinical Pathology 112:75–89. doi:10.1093/ajcp/112.1.75.
   PubMed Web of Science ®Google Scholar
• Ordóñez, N. G. 2003. The immunohistochemical diagnosis of mesothelioma: A comparative study of epithelioid mesothelioma and lung adenocarcinoma. American Journal of Surgical Pathology 27:1031–51. doi:10.1097/00000478-200308000-00001.
   PubMed Web of Science ®Google Scholar
• Ordóñez, N. G. 2013. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: A review and update. Human Pathology 44:1–19. doi:10.1016/j.humpath.2012.05.014.
   PubMed Web of Science ®Google Scholar
• Ordóñez, N. G., and A. A. Sahin. 2014. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: A comparative study. Human Pathology 45:1529–40. doi:10.1016/j.humpath.2014.03.006.
   PubMed Web of Science ®Google Scholar
• Paintal, A. 2015. The evolving role of effusion cytology in the diagnosis of malignant mesothelioma. Cytopathology 26:137–38. doi:10.1111/cyt.12252.
   PubMed Web of Science ®Google Scholar
• Peto, J., C. Rake, C. Gilham, and J. Hatch. 2009. Occupational, domestic and environmental mesothelioma risks in Britain: A case-control study. Sudbury, UK: HSE Books, Her Majesty’s Stationery Office.
   Google Scholar
• Rake, C., C. Gilham, J. Hatch, A. Darnton, J. Hodgson, and J. Peto. 2009. Occupational, domestic and environmental mesothelioma risks in the British population: A case-control study. British Journal of Cancer 100:1175–83. doi:10.1038/sj.bjc.6604879.
   PubMed Web of Science ®Google Scholar
• Sandeck, H. P., O. D. Røe, K. Kjaerheim, H. Willén, and E. Larsson. 2010. Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry. Diagnostic Pathology 5:47. doi:10.1186/1746-1596-5-47.
   PubMed Web of Science ®Google Scholar
• Sheffield, B. S., A. V. Tinker, Y. Shen, H. Hwang, H. H. Li-Chang, E. Pleasance, C. Ch’ng, A. Lum, J. Lorette, Y. J. McConnell, S. Sun, S. J. M. Jones, A. M. Gown, D. G. Huntsman, D. F. Schaeffer, A. Churg, S. Yip, J. Laskin, M. A. Marra, and S. Deb. 2015. Personalized oncogenomics: Clinical experience with malignant peritoneal mesothelioma using whole genome sequencing. PLoS ONE 10:e0119689. doi:10.1371/journal.pone.0119689.
   Google Scholar
• Tatsumori, T., K. Tsuta, K. Masai, T. Kinno, T. Taniyama, A. Yoshida, K. Suzuki, and H. Tsuda. 2015. p40 is the best marker for diagnosing pulmonary squamous cell carcinoma: Comparison with p63, cytokeratin 5/6, desmocollin-3, and sox2. Applied Immunohistochemistry & Molecular Morphology 22:377–82. doi:10.1097/PAI.0b013e3182980544.
   Web of Science ®Google Scholar
• Travis, W. D., E. Brambilla, A. P. Burke, A. Marx, and A. G. Nicholson, editors. 2015. WHO classification of tumours of the lung, pleura, thymus and heart. Lyon, France: International Agency for Research on Cancer.
   Google Scholar
• Vlasoff, D. M., D. Y. Baschinsky, and W. L. Frankel. 2002. Cytokeratin 5/6 immunostaining in hepatobiliary and pancreatic neoplasms. Applied Immunohistochemistry & Molecular Morphology 10:147–51. doi:10.1097/00129039-200206000-00009.
   Web of Science ®Google Scholar
• Wagner, J. C., C. A. Sleggs, and P. Marchand. 1960. Diffuse pleural mesothelioma and asbestos exposure in the north western Cape Province. British Journal of Industrial Medicine 17:260–71.
   PubMedGoogle Scholar
• Wang, N. S., S. N. Huang, and P. Gold. 1979. Absence of carcinoembryonic antigen-like material in mesothelioma: An immunohistochemical differentiation from other lung cancers. Cancer 44:937–43. doi:10.1002/1097-0142(197909)44:3<937::AID-CNCR2820440322>3.0.CO;2-K.
   PubMed Web of Science ®Google Scholar